Prikaz osnovnih podataka o dokumentu

dc.creatorLakić, Dragana
dc.creatorTasić, Ljiljana
dc.creatorKos, Mitja
dc.creatorOdalović, Marina
dc.creatorTadić, Ivana
dc.date.accessioned2019-09-02T11:28:33Z
dc.date.available2019-09-02T11:28:33Z
dc.date.issued2012
dc.identifier.issn1098-3015
dc.identifier.urihttps://farfar.pharmacy.bg.ac.rs/handle/123456789/1684
dc.description.abstractOBJECTIVES: Cardiovascular diseases (CVDs) imposes a burden to society in terms’ of mortality, morbidity and economic losses. The aim of this study was to estimate the cost of CVDs in Serbia in 2009 from the perspective of the society. METHODS: For the purpose of the study CVD was defined by the International Classification of Disease 10 revision, as the following diagnosis: hypertension, coronary heart dis- ease, cardiomyopathy, heart failure and cerebrovascular disease. The prevalence, top-down method was used to quantify the annual cardiovascular costs. Produc- tivity losses were estimated using the human capital approach and the friction cost method. Data were collected from Serbian Health Insurance Fund and National Public Health Institute “Batut”. A discount rate of 5% was used to convert all future lifetime earnings into the present value. RESULTS: The total direct costs of CVD in 2009 were € 400 million. The majority of total costs (€ 514.3 million) were for: medication (29.94%), hospital days (28.97%) and hospital inpatient care — surgical and diagnostic interventions (17.84%). Indirect costs (mortality and morbidity) ac- counted for 22.15% of total costs. The results showed that more than half a million working days were lost due to incapacity resulting from CVDs. The results were robust to a change in 20% of volume or the unit price of all direct and indirect cost and to discount rate 2% and 10%. CONCLUSIONS: The total CVD in 2009 repre- sented approximately 1.8% of the Serbian gross domestic product. The results of study would be valuable to health policy makers to bridge the gap between in- vested resources and needs, in order to improve cardiovascular disease outcomes.
dc.publisherElsevier Inc.
dc.rightsopenAccess
dc.sourceValue in Health
dc.titleCost of cardiovascular diseases in Serbiaen
dc.typeconferenceObject
dc.rights.licenseARR
dcterms.abstractЛакић, Драгана; Тадић, Ивана; Одаловић, Марина; Тасић, Љиљана; Кос, Митја;
dc.citation.volume15
dc.citation.issue7
dc.citation.spageA367
dc.citation.epageA367
dc.citation.other15(7): -
dc.citation.rankM21
dc.description.otherResearch poster presentations – session II
dc.description.otherDisease-specific studies: Cardiovascular disorders - cost studies
dc.description.otherISPOR 15th Annual European Congress and ISPOR 5th Asia-Pacific Conference
dc.identifier.wos000312411100480
dc.identifier.doi10.1016/j.jval.2012.08.974
dc.identifier.fulltexthttp://farfar.pharmacy.bg.ac.rs/bitstream/id/10193/Cost_of_cardiovascular_pub_2012.pdf
dc.type.versionpublishedVersion


Dokumenti

Thumbnail

Ovaj dokument se pojavljuje u sledećim kolekcijama

Prikaz osnovnih podataka o dokumentu